These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19318601)

  • 21. Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis.
    Lopez FA; Ginsberg LD; Arnold V
    Postgrad Med; 2008 Sep; 120(3):89-102. PubMed ID: 18824828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity.
    Ginsberg L; Katic A; Adeyi B; Dirks B; Babcock T; Lasser R; Scheckner B; Adler LA
    Curr Med Res Opin; 2011 Jun; 27(6):1097-107. PubMed ID: 21438796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.
    Dew RE; Kollins SH
    Expert Opin Pharmacother; 2010 Dec; 11(17):2907-13. PubMed ID: 20979573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A systematic review of the safety of lisdexamfetamine dimesylate.
    Coghill DR; Caballero B; Sorooshian S; Civil R
    CNS Drugs; 2014 Jun; 28(6):497-511. PubMed ID: 24788672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers.
    Ermer J; Homolka R; Martin P; Buckwalter M; Purkayastha J; Roesch B
    J Clin Pharmacol; 2010 Sep; 50(9):1001-10. PubMed ID: 20173084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults.
    Brown TE; Brams M; Gao J; Gasior M; Childress A
    Postgrad Med; 2010 Sep; 122(5):7-17. PubMed ID: 20861583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does prior exposure to stimulants in children with ADHD impact cardiovascular parameters from lisdexamfetamine dimesylate?
    Wigal SB; Jun A; Wong AA; Stehli A; Steinberg-Epstein R; Lerner MA
    Postgrad Med; 2010 Sep; 122(5):27-34. PubMed ID: 20861585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
    Faraone SV; Glatt SJ
    J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD.
    Waxmonsky JG; Waschbusch DA; Glatt SJ; Faraone SV
    J Clin Psychiatry; 2011 Oct; 72(10):1366-75. PubMed ID: 21367347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melatonin treatment for insomnia in pediatric patients with attention-deficit/hyperactivity disorder.
    Bendz LM; Scates AC
    Ann Pharmacother; 2010 Jan; 44(1):185-91. PubMed ID: 20028959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder.
    Adler LA; Alperin S; Leon T; Faraone SV
    J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):196-199. PubMed ID: 27935735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder.
    Brams M; Mao AR; Doyle RL
    Postgrad Med; 2008 Sep; 120(3):69-88. PubMed ID: 18824827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.
    Findling RL; Childress AC; Krishnan S; McGough JJ
    CNS Spectr; 2008 Jul; 13(7):614-20. PubMed ID: 18622366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders.
    Roncero C; Álvarez FJ
    Expert Rev Neurother; 2014 Aug; 14(8):849-65. PubMed ID: 24948428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amphetamine, past and present--a pharmacological and clinical perspective.
    Heal DJ; Smith SL; Gosden J; Nutt DJ
    J Psychopharmacol; 2013 Jun; 27(6):479-96. PubMed ID: 23539642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lisdexamfetamine dimesylate (Vyvanse) for ADHD.
    Med Lett Drugs Ther; 2007 Jul; 49(1265):58-9. PubMed ID: 17637583
    [No Abstract]   [Full Text] [Related]  

  • 38. Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder.
    Najib J; Wimer D; Zeng J; Lam KW; Romanyak N; Paige Morgan E; Thadavila A
    J Cent Nerv Syst Dis; 2017; 9():1179573517728090. PubMed ID: 28855799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adults.
    Brown TE; Brams M; Gasior M; Adeyi B; Babcock T; Dirks B; Scheckner B; Wigal T
    Curr Med Res Opin; 2011; 27 Suppl 2():23-33. PubMed ID: 21973229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lisdexamfetamine: a prodrug stimulant for ADHD.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2008 Aug; 46(8):19-22. PubMed ID: 18777964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.